Furthermore, several critical indicators for evaluating tumor immunogenicity and antigen presentation efficiency collected from the study of Thorsson et al. also indicated that the PI3K pathway mutation group displayed significantly higher neoantigen, SNV neoantigens, nonsilent mutation rate, and TCR Shannon (Fig. 4D–G) [25]. This evidence concerns the gene PIK3CA and neoplasm.